Civoxin is a novel antibiotic that falls under the class of compounds known as cyclic lipopeptides. It is primarily developed to combat drug-resistant bacterial infections, particularly those caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Civoxin's mechanism of action involves disrupting bacterial cell membrane integrity, leading to cell death. Its potential applications in treating serious infections make it an important candidate in the fight against antibiotic resistance.